IMU knows how to interpret pre-clinical trials to conclude what the most likely outcome in humans will be. That's why IMU is, based on Her-Vaxx and B-Vaxx data to date, so confident and upbeat about PD1-Vaxx. All the experience went into developing of the 3rd B-cell tech vax, the FDA / IND approval went through with no objection or improvement request ( 1 in 10.000 ) and anyone who tells us this is hyped really should think twice. The sp is not hyper, it is still hypo.
GLTA
Ann: Imugene First Patient Dosed in PD1-VAXX Clinical Trial, page-38
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |